Novo Nordisk Research Centre Oxford (NNRCO) is an innovative target discovery unit with a focus on identifying novel, game-changing therapies for patients with type 2 diabetes and cardiometabolic diseases.

They employ advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets. The site is a fusion of the best of academia, biotech and big pharma in order to realize cutting-edge biology and start a target’s journey from bench to bedside.

NNRCO operates at the boundaries of frontier science with a mandate to find dynamic, agile and distinctive new ways of working to diversify the company’s pipeline with disruptive medicines.